ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Mechanism of Yangxin Dawa Yimixike Mi Gao for myocardial ischemia/reperfusion injury: an integrative study of network pharmacology and and validation.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically elucidate the cardioprotective mechanisms of the traditional Uyghur polyherbal formulation Yangxin Dawa Yimixike Mi Gao (YXDW, ) against myocardial ischemia/ reperfusion injury through integrated chemical analysis, bioinformatics prediction, and multilevel experimental validation.
methodsUsing ultra-high-performance liquid chromatography coupled with quadrupole-Orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap-HRMS), 137 bioactive constituents were identified in YXDW. Potential targets associated with myocardial ischemia/reperfusion (I/R) injury were predicted through network pharmacology analysis and validated using Mendelian randomization (MR). Gene ontology and kyoto encyclopedia of genes and genomes enrichment analyses, together with molecular docking, were performed to identify the core regulatory pathways. An
resultsUHPLC-Q-Orbitrap-HRMS fingerprinting demonstrated high batch-to-batch consistency, with similarity values greater than 0.87, and identified 23 compounds with high oral bioavailability (OB ≥ 56%). Network pharmacology and MR analyses identified 13 key targets associated with myocardial I/R injury, including C-X-C motif chemokine receptor 1 (CXCR1), mitogen-activated protein kinase kinase 1 (MAP2K1), and poly (ADP-ribose) polymerase 1 (PARP1), which may be involved in the regulation of apoptosis, oxidative stress, and inflammatory responses.
conclusionYXDW exerts cardioprotective effects against myocardial I/R injury through multi-target modulation of inflammatory, oxidative, and apoptotic pathways. Our findings provide preliminary mechanistic support for the clinical relevance of YXDW in I/R therapy and offer a modern pharmacological basis for the rational use of traditional polyherbal formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.